Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.

Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.
Related ArticlesRisk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study. PLoS One. 2020;15(12):e0244660 Authors: Shim M, Bang WJ, Oh CY, Lee YS, Jeon SS, Ahn H, Ju YS, Cho JS Abstract Recent studies reported conflicting results on the association of androgen deprivation therapy (ADT) ... read more
Source: PubMedPublished on 2020-12-31